Penumbra, Inc. (PEN)
Automate Your Wheel Strategy on PEN
With Tiblio's Option Bot, you can configure your own wheel strategy including PEN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PEN
- Rev/Share 32.1584
- Book/Share 31.4526
- PB 8.4422
- Debt/Equity 0.1819
- CurrentRatio 6.3021
- ROIC 0.0666
- MktCap 10282888227.0
- FreeCF/Share 3.8984
- PFCF 68.4016
- PE 242.4507
- Debt/Assets 0.1385
- DivYield 0
- ROE 0.0365
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | PEN | BofA Securities | -- | Buy | -- | $320 | March 14, 2025 |
| Initiation | PEN | UBS | -- | Buy | -- | $305 | Jan. 21, 2025 |
| Initiation | PEN | Oppenheimer | -- | Outperform | -- | $275 | Dec. 17, 2024 |
| Upgrade | PEN | Wells Fargo | Equal Weight | Overweight | $190 | $275 | Dec. 11, 2024 |
| Initiation | PEN | Stifel | -- | Buy | -- | $238 | Sept. 18, 2024 |
| Initiation | PEN | Leerink Partners | -- | Outperform | -- | $263 | Sept. 3, 2024 |
News
Why Is Penumbra (PEN) Down 10.6% Since Last Earnings Report?
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Negative
Penumbra (PEN) reported earnings 30 days ago. What's next for the stock?
Read More
Penumbra Rallies 35.9% in a Year: What's Driving the Stock?
Published: May 22, 2025 by: Zacks Investment Research
Sentiment: Positive
PEN has shown notable strength over the past year, driven by the performance of its core U.S. thrombectomy business. Solid international prospects instill optimism.
Read More
Penumbra, Inc. to Present at Upcoming Investor Conferences
Published: May 20, 2025 by: PRNewsWire
Sentiment: Neutral
ALAMEDA, Calif. , May 20, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the following investor conferences on the dates and times listed below.
Read More
Here's Why Penumbra (PEN) is a Strong Momentum Stock
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Here's Why Penumbra (PEN) is a Strong Growth Stock
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
3 Mid-Cap Medical Stocks Outperforming the Market
Published: May 06, 2025 by: MarketBeat
Sentiment: Positive
While major market indexes like the S&P 500 have struggled to gain traction in 2025 and remain in the red YTD, certain pockets of the market are showing impressive strength. Several medical and biotechnology sector mid-cap stocks have stood out for their resilience and outperformance.
Read More
3 Reasons Growth Investors Will Love Penumbra (PEN)
Published: April 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Read More
Why Penumbra (PEN) is a Top Growth Stock for the Long-Term
Published: April 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Penumbra Q1 Earnings & Revenues Top Estimates, Stock Up, Margins Expand
Published: April 24, 2025 by: Zacks Investment Research
Sentiment: Positive
PEN reports better-than-expected earnings and revenues in the first quarter of 2025.
Read More
Why Penumbra (PEN) is Poised to Beat Earnings Estimates Again
Published: April 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Penumbra (PEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Reasons to Retain Penumbra Stock in Your Portfolio for Now
Published: April 08, 2025 by: Zacks Investment Research
Sentiment: Positive
PEN continues to attract investor interest with its strong Thrombectomy business and portfolio expansion efforts.
Read More
New Thrombectomy Product Launches Support PEN Stock Amid Macro Issues
Published: March 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Penumbra expects to materially increase both revenues and profitability in the company's international business in the next few years.
Read More
Penumbra, Inc. Announces Don Kassing will Retire from Board of Directors
Published: February 21, 2025 by: PRNewsWire
Sentiment: Neutral
ALAMEDA, Calif. , Feb. 21, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced today that after 17 years of distinguished service, Don Kassing has notified the company that he will retire from the board of directors effective April 1, 2025.
Read More
Penumbra (PEN) Upgraded to Buy: Here's Why
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Penumbra (PEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Penumbra, Inc. (PEN) Q4 2024 Earnings Call Transcript
Published: February 18, 2025 by: Seeking Alpha
Sentiment: Neutral
Penumbra, Inc. (NYSE:PEN ) Q4 2024 Earnings Conference Call February 18, 2025 4:30 PM ET Company Participants Cecilia Furlong - Director of Business Development and Investor Relations Adam Elsesser - Chairman & Chief Executive Officer Maggie Yuen - Chief Financial Officer Jason Mills - Executive Vice President of Strategy Conference Call Participants Larry Biegelsen - Wells Fargo Securities Robert Marcus - JPMorgan Pito Chickering - Deutsche Bank Bill Plovanic - Canaccord Richard Newitter - Truist Securities Samantha Kurtz - Piper Sandler Michael Sarcone - Jefferies Ryan Zimmerman - BTIG Shagun Singh - RBC Capital Markets Michael Kratky - Leerink Partners …
Read More
Here's What Key Metrics Tell Us About Penumbra (PEN) Q4 Earnings
Published: February 18, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Penumbra (PEN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Should You Add Penumbra Stock to Your Portfolio Right Now?
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Positive
PEN continues to attract investor interest with its strong portfolio expansion and global expansion efforts.
Read More
About Penumbra, Inc. (PEN)
- IPO Date 2015-09-18
- Website https://www.penumbrainc.com
- Industry Medical - Devices
- CEO Mr. Adam Elsesser J.D.
- Employees 4500